HeartStart XL+ Defibrillator/Monitor 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Philips Medical Systems 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2015-07-06
  • 사례 출판 날짜
    2015-07-06
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: philips medical systems heartstart xl+ defibrillator/monitor the australia therapeutic goods administration (tga) has posted a medical device safety alert concerning philips heartstart xl+ defibrillator/monitor manufactured by philips medical systems. the affected heartstart xl+ defibrillator/monitor units include serial numbers within the following ranges: uso1100100 to usd1101095 us11201096 to usd1203968 us11303969 to usd1309471 us11409472 to us61414022 the manufacturer has identified the following xl+ software and hardware issues:- software issues: the xl+ may fail to complete the power on sequence and continuously reboot. the xl+ may either fail to power up or may shut down unexpectedly. the xl+ may have a software version that did not reset a fail-safe monitoring component which could delay of therapy or pacing interruption. the xl+ may fail to generate verbal prompts in automated external defibrillator (aed) mode. hardware issues: the xl+ may have been manufactured with a speaker that may fail. the battery may not seat properly causing the xl+ to shut down unexpectedly or remain powered on and not acknowledge or charge the battery. the xl+ exceeds the allowable radiated emissions level for class b cispr11. the xl+ ecg signal from leads could be lost and unrecoverable. the xl+ spo2 signal may lose communication and cause the device to reboot. the xl+ battery detection system may be disrupted and cause a false low battery alarm according to the alert, the manufacturer will contact customers with affected devices to arrange for installation of the software and hardware upgrades. in the interim, the manufacturer advises users that they can continue to use their xl+ prior to receiving the software and hardware upgrades, provided they should identify a readily available backup defibrillator to use in the event the affected heartstart xl+ exhibits any of these issues. for details, please refer to the tga website: http://apps.Tga.Gov.Au/prod/sara/arn-detail.Aspx?k=rc-2015-rn-00588-1 if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 6 july 2015.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: [6 Jul 2015] Philips Medical Systems HeartStart XL+ Defibrillator/Monitor
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • Source
    DH